ADC Therapeutics SA (ADCT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue, net | 18,839 | 23,033 | 18,464 | 17,410 |
| Selling and marketing | 10,147 | 10,553 | 10,673 | 10,701 |
| Restructuring and impairment expenses | 13,091 | - | - | - |
| Research and development | 30,090 | 28,928 | 32,502 | 24,295 |
| General and administrative | 8,822 | 9,955 | 10,002 | 10,238 |
| Cost of product sales | 836 | 2,061 | 851 | 1,217 |
| Total operating expense | 62,986 | 51,497 | 54,028 | 46,451 |
| Loss from operations | -44,147 | -28,464 | -35,564 | -29,041 |
| Interest expense | - | 12,230 | 13,117 | 12,679 |
| Other, net | -182 | 203 | 1,624 | 2,754 |
| Interest income | 1,934 | 2,054 | 3,438 | 3,253 |
| Interest expense | 12,997 | - | - | - |
| Total other expense, net | -11,245 | -9,973 | -8,055 | -6,672 |
| Loss before income taxes | -55,392 | -38,437 | -43,619 | -35,713 |
| Income tax expense | 1,254 | 165 | 90 | 234 |
| Loss before equity in net losses of joint venture | -56,646 | -38,602 | -43,709 | -35,947 |
| Equity in net losses of joint venture | - | - | -260 | -597 |
| Net loss | -56,646 | -38,602 | -43,969 | -36,544 |
| Net loss per share, basic (in dollars per share) | -0.5 | -0.36 | -0.42 | -0.38 |
| Net loss per share, diluted (in dollars per share) | -0.5 | -0.36 | -0.42 | -0.38 |
| Weighted average shares outstanding, basic (in shares) | 113,743,358 | 107,202,374 | 104,824,877 | 95,691,245 |
| Weighted average shares outstanding, diluted (in shares) | 113,743,358 | 107,202,374 | 104,824,877 | 95,691,245 |